Filtered By:
Source: International Immunopharmacology
Vaccination: Cancer Vaccines

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 74 results found since Jan 2013.

A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies
CONCLUSION: Our findings highlight the substantially low rate of seroprotection in patients with hematological malignancies with a wide range of rates among disease subgroups and different treatments; further highlighting the fact that booster doses might be acquired for these patients to improve immunity against SARS-CoV-2.PMID:35843148 | PMC:PMC9273573 | DOI:10.1016/j.intimp.2022.109046
Source: International Immunopharmacology - July 17, 2022 Category: Allergy & Immunology Authors: Maryam Noori Shadi Azizi Farhan Abbasi Varaki Seyed Aria Nejadghaderi Davood Bashash Source Type: research

Anti-tumor activity of a peptide combining patterns of insect alloferons and mammalian immunoglobulins in naïve and tumor antigen vaccinated mice.
Abstract Alloferons are a group of naturally occurring peptides primarily isolated from insects and capable of stimulating mouse and human NK cell cytotoxicity towards cancer cells. In this paper we examined anti-tumor activity of alloferon-1 and its novel structural analog referred to as allostatin. The activity was tested in naïve and preventively tumor antigen vaccinated DBA/2 mice subcutaneously grafted with syngenic P388D1 mouse leukemia cells. In naïve animals allostatin demonstrated tumoristatic activity prevailing over alloferon-1 effect. The preventive vaccination caused only weak tumoristatic effect in...
Source: International Immunopharmacology - October 29, 2013 Category: Allergy & Immunology Authors: Chernysh S, Kozuharova I Tags: Int Immunopharmacol Source Type: research

Administration of COVID-19 vaccines in immunocompromised patients
Int Immunopharmacol. 2021 Jul 28;99:108021. doi: 10.1016/j.intimp.2021.108021. Online ahead of print.ABSTRACTSince the beginning of vaccination programs against COVID-19 in different countries, several populations such as patients with specific immunological conditions have been considered as the priorities for immunization. In this regard, patients with autoimmune diseases or those receiving immunosuppressive agents and anti-cancer therapies, need special attention. However, no confirmed data is presently available regarding COVID-19 vaccines in these populations due to exclusion from the conducted clinical trials. Given ...
Source: International Immunopharmacology - August 5, 2021 Category: Allergy & Immunology Authors: Manica Negahdaripour Mojtaba Shafiekhani Seyed Mohammad Iman Moezzi Sogand Amiri Shiva Rasekh Ashkan Bagheri Pouria Mosaddeghi Afsaneh Vazin Source Type: research

Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study
CONCLUSIONS: These findings suggest that simple and widely available peripheral counts of T helper and B cells correlate with humoral response to mRNA-BNT162b2 vaccine in actively treated cancer patients. Upon validation, our results could provide additional insights into the predictive assessment of vaccination efficacy.PMID:35461110 | PMC:PMC9008127 | DOI:10.1016/j.intimp.2022.108774
Source: International Immunopharmacology - April 23, 2022 Category: Allergy & Immunology Authors: Fabrizio Nelli Agnese Fabbri Valentina Panichi Diana Giannarelli Giuseppe Topini Julio R Giron Berrios Antonella Virtuoso Eleonora Marrucci Marco Mazzotta Marta Schirripa Carlo Signorelli Mario G Chilelli Francesca Primi Maria A Silvestri Enzo M Ruggeri Source Type: research

An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations
This study describes the structural features and technologies used in producing of COVID-19 mRNA-based vaccines as the most influential factor in controlling this pandemic and a successful pattern for planning to produce other kind of genetic vaccines against infections or cancers.PMID:36867924 | PMC:PMC9968612 | DOI:10.1016/j.intimp.2023.109934
Source: International Immunopharmacology - March 3, 2023 Category: Allergy & Immunology Authors: Mona Sadat Mirtaleb Reza Falak Jalal Heshmatnia Behnaz Bakhshandeh Ramezan Ali Taheri Hoorieh Soleimanjahi Reza Zolfaghari Emameh Source Type: research

Breast cancer immunotherapy: Current and novel approaches
Int Immunopharmacol. 2021 Jun 18;98:107886. doi: 10.1016/j.intimp.2021.107886. Online ahead of print.ABSTRACTThe crucial role of the immune system in the progression/regression of breast cancer (BC) should always be taken into account. Various immunotherapy approaches have been investigated for BC, including tumor-targeting antibodies (bispecific antibodies), adoptive T cell therapy, vaccines, and immune checkpoint blockade such as anti-PD-1. In addition, a combination of conventional chemotherapy and immunotherapy approaches contributes to improving patients' overall survival rates. Although encouraging outcomes have been...
Source: International Immunopharmacology - June 21, 2021 Category: Allergy & Immunology Authors: Khadijeh Barzaman Shima Moradi-Kalbolandi Aysooda Hosseinzadeh Mohammad Hossein Kazemi Hossein Khorramdelazad Elahe Safari Leila Farahmand Source Type: research

A novel era of cancer/testis antigen in cancer immunotherapy
Int Immunopharmacol. 2021 Jun 23;98:107889. doi: 10.1016/j.intimp.2021.107889. Online ahead of print.ABSTRACTImmunotherapy is a regimen that is especially utilized in many advanced cancers. Tumor antigens include tumor-specific antigens and tumor-associated antigens, and they function as targets for immunotherapy, such as cancer vaccines and autologous T cells. Cancer/testis antigens (CTAs), which is a group of genes that are restrictedly expressed in malignant cells as well as some germline cells, are tumor-associated antigens. These expression characteristics make CTAs promising candidates for vaccine or T cell therapy t...
Source: International Immunopharmacology - June 26, 2021 Category: Allergy & Immunology Authors: Xiaoyan Meng Xueqing Sun Zhonglong Liu Yue He Source Type: research

Anti-cancer immunoprotective effects of immunization with hydatid cyst wall antigens in a non-immunogenic and metastatic triple-negative murine mammary carcinoma model
Int Immunopharmacol. 2021 Jul 8;99:107955. doi: 10.1016/j.intimp.2021.107955. Online ahead of print.ABSTRACTCancer vaccines have gained lots of attention as the future of cancer treatment. However, poor immunogenicity of tumor-associated antigens often fails to induce an efficient immune response against the tumor. Strange anti-tumor immune responses at the parasite-infected patients due to cross-reactivity have been reported in various studies. Therefore, parasite antigens with significant immunogenicity and high epitope homology with cancer antigens may activate a strong immune response against cancer cells. Herein, the ...
Source: International Immunopharmacology - July 11, 2021 Category: Allergy & Immunology Authors: Mahshid Shakibapour Amirhosein Kefayat Mohammad Reza Mofid Behrokh Shojaie Fereshteh Mohamadi Seydeh Maryam Sharafi Mahdi Mahmoudzadeh Hossein Yousofi Darani Source Type: research

Mannose-modified liposome designed for epitope peptide drug delivery in cancer immunotherapy
CONCLUSIONS: we successfully constructed a new polypeptide liposome drug delivery system by avoiding the disadvantages of single use of dominant epitope peptide drugs and accurate targeted therapy for tumors.PMID:34653955 | DOI:10.1016/j.intimp.2021.108148
Source: International Immunopharmacology - October 15, 2021 Category: Allergy & Immunology Authors: Jiankun Yu Shanshan Wang Jing Qi Zhaojin Yu Yunkai Xian Wensi Liu Xiangyi Wang Chao Liu Minjie Wei Source Type: research

Anti-tumour effect of in situ vaccines combined with VEGFR inhibitors in the treatment of metastatic cervical cancer
In conclusion, our preclinical research results showed that the combination of in situ vaccine and anti-angiogenic therapy has a good anti-tumor effect, and may potentially offer an effective treatment option for patients with advanced cervical cancer.PMID:34717193 | DOI:10.1016/j.intimp.2021.108302
Source: International Immunopharmacology - October 30, 2021 Category: Allergy & Immunology Authors: Lixiao Liu Luya Cai Xuedan Du Jinduo Zhao Ye Zhao Chengyang Zou Shanshan Yu Chunhong Zhang Piaopiao Ye Xiaoping Su Xiaojian Yan Wenfeng Li Source Type: research